Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions

This article was originally published in PharmAsia News

Executive Summary

As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma
Advertisement

Related Content

India-Style Patent Laws Targeted In Trans-Pacific Trade Negotiations
Biologics Exclusivity Flares Up At TTP Talks In Singapore
U.S. Law On 12-Year Biologics Data Exclusivity Remains Stumbling Block To Trans-Pacific Partnership Agreement
Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says
Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits
Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report
Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Abbott, BMS Suffer Blows On Antiretrovirals Kaletra and Reyataz As Indian Patent Office Rejects Patent Claims
Latin American Trade Agreements Loosen Pharmaceutical IP Rules
Advertisement
UsernamePublicRestriction

Register

SC078585

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel